Baird R W Lowers Catalent (NYSE:CTLT) to Hold

Baird R W downgraded shares of Catalent (NYSE:CTLT) from a strong-buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

A number of other analysts also recently issued reports on the stock. StockNews.com assumed coverage on shares of Catalent in a report on Wednesday, September 18th. They set a sell rating for the company. William Blair reissued a market perform rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada reaffirmed a sector perform rating and issued a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an equal weight rating in a research note on Friday, June 28th. Finally, Robert W. Baird reiterated a neutral rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus target price of $59.83.

Catalent Trading Up 0.7 %

Shares of CTLT stock opened at $60.29 on Tuesday. The company has a market capitalization of $10.91 billion, a price-to-earnings ratio of -9.88, a PEG ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The company has a 50-day simple moving average of $59.64 and a two-hundred day simple moving average of $57.31. Catalent has a 52-week low of $31.80 and a 52-week high of $61.20.

Catalent (NYSE:CTLT) last issued its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. Research analysts anticipate that Catalent will post 0.85 EPS for the current fiscal year.

Insider Activity

In other news, insider Ricky Hopson sold 662 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, SVP Scott Gunther sold 666 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ricky Hopson sold 662 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,409 shares of company stock valued at $782,923. 0.31% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CTLT. Lindbrook Capital LLC grew its holdings in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the period. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalent during the 2nd quarter worth approximately $42,000. Mather Group LLC. acquired a new stake in shares of Catalent during the first quarter worth about $52,000. Longfellow Investment Management Co. LLC lifted its stake in Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after buying an additional 305 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after purchasing an additional 212 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.